[Effect of human recombinant beta-interferon on natural killer activity of peripheral lymphocytes in cancer patients]. 1985

T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita

After human recombinant beta-interferon (ReIFN-beta) was administered to 13 cancer patients intrathoracoperitoneally and by intravenous drip infusion every day or 3 times a week, the effect of peripheral lymphocytes on natural killer (NK) activity was studied. When ReIFN-beta was given every day or 3 times a week, the NK activity was notably enforced, and was maintained throughout the period of administration. NK activity was also enforced regardless of whether ReIFN-beta was given intravenously on intrathoracoperitoneally. By the administration of ReIFN-beta, pleural effusion and ascites in three patients were depleted, and in one patient, Douglas' cul-de-sac tumor disappeared. It was therefore suggested that ReIFN-beta was effective against the cavity of carcinomatosis.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
August 1987, Gastroenterologia Japonica,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
January 1994, Mediators of inflammation,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
January 1982, Immunology letters,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
October 1982, Antibiotiki,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
June 1989, Zhonghua wai ke za zhi [Chinese journal of surgery],
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
February 1982, Cellular immunology,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
August 1996, Cellular immunology,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
January 1988, International journal of immunopharmacology,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
May 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Beika, and N Tanaka, and J Yamada, and A Hizuta, and K Onishi, and Y Akura, and K Hirose, and K Orita
July 1985, Japanese journal of cancer research : Gann,
Copied contents to your clipboard!